CN103649108B - 环孢素a的晶型、制备方法及其使用方法 - Google Patents

环孢素a的晶型、制备方法及其使用方法 Download PDF

Info

Publication number
CN103649108B
CN103649108B CN201280033382.7A CN201280033382A CN103649108B CN 103649108 B CN103649108 B CN 103649108B CN 201280033382 A CN201280033382 A CN 201280033382A CN 103649108 B CN103649108 B CN 103649108B
Authority
CN
China
Prior art keywords
crystal formation
eye
ciclosporin
formation according
csa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280033382.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103649108A (zh
Inventor
K·卡拉米
R·S·格雷厄姆
A·V·戈雷
S·W·史密斯
吴科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46178866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103649108(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN103649108A publication Critical patent/CN103649108A/zh
Application granted granted Critical
Publication of CN103649108B publication Critical patent/CN103649108B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201280033382.7A 2011-05-27 2012-05-25 环孢素a的晶型、制备方法及其使用方法 Expired - Fee Related CN103649108B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490887P 2011-05-27 2011-05-27
US61/490,887 2011-05-27
PCT/US2012/039611 WO2012166610A1 (en) 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Publications (2)

Publication Number Publication Date
CN103649108A CN103649108A (zh) 2014-03-19
CN103649108B true CN103649108B (zh) 2017-03-29

Family

ID=46178866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280033382.7A Expired - Fee Related CN103649108B (zh) 2011-05-27 2012-05-25 环孢素a的晶型、制备方法及其使用方法

Country Status (19)

Country Link
US (4) US8772245B2 (cg-RX-API-DMAC7.html)
EP (2) EP2714720B1 (cg-RX-API-DMAC7.html)
JP (1) JP6163482B2 (cg-RX-API-DMAC7.html)
KR (1) KR102079402B1 (cg-RX-API-DMAC7.html)
CN (1) CN103649108B (cg-RX-API-DMAC7.html)
AR (1) AR086586A1 (cg-RX-API-DMAC7.html)
AU (4) AU2012262513B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013030554B1 (cg-RX-API-DMAC7.html)
CA (1) CA2836946C (cg-RX-API-DMAC7.html)
CL (1) CL2013003400A1 (cg-RX-API-DMAC7.html)
IL (2) IL229475A0 (cg-RX-API-DMAC7.html)
MX (1) MX362271B (cg-RX-API-DMAC7.html)
MY (1) MY180581A (cg-RX-API-DMAC7.html)
RU (1) RU2602062C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201607344UA (cg-RX-API-DMAC7.html)
TW (1) TWI554522B (cg-RX-API-DMAC7.html)
UA (1) UA113627C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012166610A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201308665B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102029513B1 (ko) * 2011-11-15 2019-10-07 알러간, 인코포레이티드 사이클로스포린 제2형의 지속 작용 제형
JP6363506B2 (ja) 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤
CN108714137B (zh) * 2011-11-15 2022-02-01 阿勒根公司 环孢菌素a形式2的可热压性悬浮液
CN104039813B (zh) 2011-11-15 2017-08-29 阿勒根公司 环孢菌素a形式2及其制备方法
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US10524661B2 (en) * 2013-06-12 2020-01-07 Proactive Live, Inc. Sleep monitoring and stimulation
RU2713953C2 (ru) * 2014-07-18 2020-02-11 Аллерган, Инк. Суспензионные составы циклоспорина а для субконъюнктивального и периокулярного введения
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Mebmt側鏈已環化之環孢菌素衍生物
US10443292B2 (en) * 2016-04-25 2019-10-15 Magna Closures, Inc. Non-contact obstacle detection system for motor vehicles
US12037415B2 (en) * 2017-05-17 2024-07-16 Yuyu Pharma, Inc. Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
US20240342086A1 (en) * 2021-08-20 2024-10-17 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
US20260132169A1 (en) 2022-10-20 2026-05-14 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide crystals
CN120731215A (zh) 2023-03-20 2025-09-30 中外制药株式会社 用于产生环肽的共晶的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2211848A (en) * 1987-12-21 1989-07-12 Sandoz Ltd Orthorhomic ciclosporin crystals
WO2009088570A1 (en) * 2008-01-04 2009-07-16 Sirion Therapeutics, Inc. Stable aqueous cyclosporin compositions
CN101687013A (zh) * 2007-05-04 2010-03-31 阿勒根公司 环孢菌素在治疗具有人工晶状体的患者中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2211848A (en) * 1987-12-21 1989-07-12 Sandoz Ltd Orthorhomic ciclosporin crystals
CN101687013A (zh) * 2007-05-04 2010-03-31 阿勒根公司 环孢菌素在治疗具有人工晶状体的患者中的用途
WO2009088570A1 (en) * 2008-01-04 2009-07-16 Sirion Therapeutics, Inc. Stable aqueous cyclosporin compositions

Also Published As

Publication number Publication date
JP2014515372A (ja) 2014-06-30
ZA201308665B (en) 2014-07-30
AU2019204192A1 (en) 2019-07-04
BR112013030554B1 (pt) 2020-12-15
NZ719272A (en) 2017-10-27
US8772245B2 (en) 2014-07-08
CA2836946C (en) 2017-08-01
US20130023482A1 (en) 2013-01-24
AU2012262513A1 (en) 2013-12-12
UA113627C2 (xx) 2017-02-27
TWI554522B (zh) 2016-10-21
AR086586A1 (es) 2014-01-08
EP3521302A1 (en) 2019-08-07
RU2602062C2 (ru) 2016-11-10
US20140315827A1 (en) 2014-10-23
BR112013030554A2 (pt) 2016-09-06
AU2019204192B2 (en) 2021-02-04
US9206228B2 (en) 2015-12-08
MY180581A (en) 2020-12-02
JP6163482B2 (ja) 2017-07-12
WO2012166610A1 (en) 2012-12-06
US20160083432A1 (en) 2016-03-24
AU2017265008A1 (en) 2017-12-07
MX362271B (es) 2019-01-10
KR20140047054A (ko) 2014-04-21
NZ618213A (en) 2016-05-27
CA2836946A1 (en) 2012-12-06
IL229475A0 (en) 2014-01-30
AU2016203990A1 (en) 2016-06-30
EP2714720A1 (en) 2014-04-09
EP2714720B1 (en) 2018-12-26
RU2013155033A (ru) 2015-07-20
CN103649108A (zh) 2014-03-19
US20210269484A1 (en) 2021-09-02
SG10201607344UA (en) 2016-10-28
KR102079402B1 (ko) 2020-02-19
TW201311730A (zh) 2013-03-16
MX2013013855A (es) 2014-02-17
IL290158A (en) 2022-03-01
AU2012262513B2 (en) 2016-03-17
CL2013003400A1 (es) 2014-08-18

Similar Documents

Publication Publication Date Title
US20210269484A1 (en) Crystalline form of cyclosporin a, methods of preparation, and methods for use thereof
US9238002B2 (en) Suspensions of cyclosporin A form 2
RU2639393C2 (ru) Состав пролонгированного действия циклоспорина формы 2
JP6513755B2 (ja) シクロスポリンaの形態2およびその作製方法
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
WO2006137426A1 (ja) 角結膜疾患の予防又は治療剤
HK1193117B (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
HK1193117A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
NZ719272B2 (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
NZ618213B2 (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
CN107427525A (zh) 以诺龙或其酯、美替诺龙或其酯作为有效成分的干眼症治疗剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193117

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1193117

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170329

CF01 Termination of patent right due to non-payment of annual fee